Invention Grant
US08227661B2 Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions
失效
鉴定改善或调节PRO1328基因中断影响的药物的方法
- Patent Title: Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions
- Patent Title (中): 鉴定改善或调节PRO1328基因中断影响的药物的方法
-
Application No.: US12907655Application Date: 2010-10-19
-
Publication No.: US08227661B2Publication Date: 2012-07-24
- Inventor: Joel A. Edwards , Wenhu Huang , Charles Montgomery , Ni Nancy Qian , Zheng-Zheng Shi , Mary Jean Sparks , Peter Vogel , Mindy Oox
- Applicant: Joel A. Edwards , Wenhu Huang , Charles Montgomery , Ni Nancy Qian , Zheng-Zheng Shi , Mary Jean Sparks , Peter Vogel , Mindy Oox
- Applicant Address: US TX The Woodlands
- Assignee: Lexicon Genetics, Inc.
- Current Assignee: Lexicon Genetics, Inc.
- Current Assignee Address: US TX The Woodlands
- Agency: Arnold & Porter LLP
- Agent Bonny Yeung; Jeffery P. Bernhardt
- Main IPC: G01N33/00
- IPC: G01N33/00 ; A01K67/00 ; A01K67/027
Abstract:
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
Public/Granted literature
- US20110093960A1 Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions Public/Granted day:2011-04-21
Information query
